Roncoleukin, 0.5 mg/ml 1 ml 3 pcs
€105.25 €91.21
Pharmacotherapeutic group
Cytokine
ATC code
L03AC
.Pharmacological (immunobiological) properties
Interleukin-2 is produced by a subpopulation of T lymphocytes (T-helper I) in response to antigenic stimulation. The synthesized IL-2 affects T-lymphocytes, increasing their proliferation and subsequent synthesis of IL-2.
The biological effects of IL-2 are mediated by its binding to specific receptors present on various cellular targets.
IL-2 specifically affects the growth, differentiation and activation of T- and B-lymphocytes, monocytes, macrophages, oligodendroglial cells and Langerhans cells. The development of cytolytic activity of natural killer and cytotoxic
T-lymphocytes depends on its presence. IL-2 causes formation of lymphokine-activated killer cells and activates tumor-infiltrating cells.
The expansion of the spectrum of lysing effector cells causes elimination of a variety of pathogens, infected and malignant cells, which provides immune protection directed against tumor cells as well as pathogens of viral, bacterial and fungal infection.
Indications
Composition
Active ingredients:
Human recombinant interleukin-2 0.25 mg, 0.5 mg, or 1 mg (=250,000 IU / 500,000 IU / 1,000,000 IU);
Additives:
sodium lauryl sulfate, 2.5 mg / 5 mg / 10 mg;
mannitol, 12.5 mg / 25 mg / 50 mg;
p> dithiotreitol – 0.08 mg;
ammonium bicarbonate – 0.79 mg;
water for injection – up to 1 ml.
How to take, the dosage
Roncoleukin® is administered once daily by subcutaneous or intravenous drops of 0.5-1.0 mg at 1 to 3 day intervals, for a course of 1-3 injections. For intravenous administration the drug from the ampoule is transferred into 400 ml of isotonic sodium chloride solution for injection. Infusion of the entire solution volume is carried out by drip for 4-6 hours. The drug solution should be clear, colorless and contain no foreign substances.
The immunotherapy with Roncoleukinà is carried out after completion of emergency and urgent surgical interventions aimed at elimination of life-threatening consequences of the underlying disease/trauma, sanation and adequate drainage of the infectious focus.
In the treatment of severe sepsis, one to three courses of Roncoleukinà are given. The course includes two intravenous infusions at a dose of 0.5 mg every other day. The criterion for prescribing the second and third courses of Roncoleukinà is lymphopenia (absolute and/or relative) that persists during treatment.
In case of newly diagnosed infiltrative destructive pulmonary tuberculosis – 3 intravenous infusions of Roncoleukin® at a dose of 0.5 mg with an interval of 48 hours against the background of specific polychemotherapy.
For preoperative preparation in advanced fibrotic cavernous tuberculosis (FCT) of the lungs against the background of specific polychemotherapy:
In unilateral FCT – 3 IV injections of Roncoleukin® 1 mg at 48-hour intervals;
in advanced pulmonary FCT with bilateral focal dissemination – 7 IV injections of Roncoleukin®: 3 injections during the first week of 1 mg at 48-hour intervals, then 1 mg twice a week for two weeks. The recommended course of immunotherapy should be completed 7 to 10 days before surgery.
The administration of Roncoleukin® in pulmonary tuberculosis is inadvisable if the body weight deficit is more than 30%.
The course of treatment with Roncoleukin® for disseminated and locally advanced forms of renal cell cancer includes:
– a single p/c or IV infusion of the drug at a dose of 0.5 mg 24 hours before surgery;
– as part of an 8-week course of immunochemotherapy at 2.0 mg IV every other day for the first four weeks of treatment. Repeated courses are given 1 to 2 months later.
In children Roncoleukinà is used as an intravenous drip. The regimens are the same as in adults. The drug is diluted in 0.9% isotonic sodium chloride solution for injection. The single dose of the drug and the volume of isotonic solution in children depends on their age:
from 0 to 1 month. – 0.1 mg in 30-50 ml of solution;
From 1 month to 1 year – 0.125 mg in 100 ml of solution;
– from 1 to 7 years – 0.25 mg in 200 ml of solution;
– over 7 years – 0.5 mg in 200 ml of solution;
– over 14 years – 0.5 mg in 400 ml of solution.
Interaction
Special Instructions
Contraindications
Side effects
Overdose
Weight | 0.022 kg |
---|---|
Shelf life | 2 years |
Conditions of storage | The drug is stored at temperatures from 2°C to 8°C. |
Manufacturer | Biotech NPK, Russia |
Medication form | Infusion and intravenous solution |
Brand | Biotech NPK |
Other forms…
Related products
Buy Roncoleukin, 0.5 mg/ml 1 ml 3 pcs with delivery to USA, UK, Europe and over 120 other countries.